Biomerieux SA

BMXMF · NYSE

$100.57+$5.57 (+5.86%)TodayMarket closed · Oct 15, 3:15 PM ET

No price history for this range.

About BMXMF

bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The company employs 15,226 full-time employees The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The firm also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

Employees: 15,226
Headquarters: Craponne, Auvergne-Rhone-Alpes
Listed: Jun 7, 2004
Sector: Health Care
Industry: Health Care Equipment & Supplies
Website: biomerieux.com

Leadership

Biomerieux SA executives
Name	Title	Since	Age
Alexandre Merieux	—	—	51
Pierre Boulud	—	—	—
Guillaume Bouhours	—	—	48
Audrey Dauvet	—	—	—
Valerie Leylde	—	2022	—
Pierre Charbonnier	—	—	—
Charles Cooper	—	—	—
Yasha Mitrotti	—	2024	—
Jennifer Zinn	—	—	—
Celine Roger-Dalbert	—	—	—
Philippe Archinard	—	—	65
Jean-Luc Belingard	—	2006	76
Harold Boeel	—	—	60
Marie-Helene Habert-Dassault	—	—	60
Sylvain Orenga	—	—	59
Marie-Paule Kieny	—	—	69
Fanny Letier	—	—	46
Viviane Monges	—	—	61

Similar companies

Companies in the same industry as Biomerieux SA

FOCLADR$4.20+3.19%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.